Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MGAM | O43451 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | SI | P14410 | 2/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | GIPR | P48546 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10309504 | 1.00 | POLB (0.43) | POLBMGAMGAASIMGAM2 | |
| SCHEMBL4071129 | 0.76 | RAB9A (0.51) | POLBCYP2A6L3MBTL1RAB9AMEN1 | |
| SCHEMBL10252926 | 0.71 | MGAM (0.41) | MGAMGAASIMGAM2L3MBTL1 | |
| SCHEMBL13422352 | 0.70 | CYP2A6 (0.58) | POLBCYP2A6RAB9AMEN1KMT2A | |
| SCHEMBL7899391 | 0.69 | ALDH1A1 (0.54) | POLBMGAMGAASIMGAM2 | |
| SCHEMBL30253453 | 0.68 | CYP2A6 (0.56) | CYP2A6L3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL10456611 | 0.68 | CYP2A6 (0.56) | CYP2A6L3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL12520194 | 0.67 | CYP2A6 (0.59) | CYP2A6RAB9AMEN1KMT2A | |
| SCHEMBL2758626 | 0.67 | CYP2A6 (0.55) | CYP2A6RAB9A | |
| SCHEMBL20910115 | 0.67 | CYP2A6 (0.65) | CYP2A6RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735604-B2 | Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120178789-A1 | NOVEL PYRROLIDINES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME LLC | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178789-A1 | NOVEL PYRROLIDINES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | POLB 2844/4885MGAM 3160/4885GAA 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.